Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…From Ajinomoto Althea, Inc. – Mon, 10 Apr 2017 16:20:15 GMT – View all San Diego jobs
Kelly Scientific is seeking Research Associates. We have a number of open positions with our clients in San Diego. Seeking candidates with experience in ELISA, cell culture, PCR, or HPLC. Degree in a life science required. Local candidates only.
Nationally Recognized Marketing Agency
Online Marketing and Social Media Agency is now hiring and Inside Sales Consultant to sell an online marketing platform including – Social Media, Facebook marketing, SEO.and other digital marketing solutions to […
SAN DIEGO, April 10, 2017 /PRNewswire/ — Dthera Sciences (OTC: DTHR), a Digital Therapeutics company based in San Diego that is working to improve quality of life and reduce anxiety in patients with Alzheimer’s and Dementia, announced the results of a clinical study conducted at University of California San Diego School of Medicine, which demonstrated positive results of its product, ReminX on patients with Alzheimer’s and Dementia. The study was conducted by J. Vincent Filoteo, PhD, Professor of Psychiatry and Neuropsychology Section Chief in the Department of Psychiatry at UC San Diego School of Medicine.
“The results of this proof-of-concept study are very promising and have the potential to help herald a new way to deliver a form of relief to patients suffering with dementia and related anxiety or depression. Our results indicate that the use of this software led to an immediate and significant decrease in anxiety and depression in our patients, which was also observed by their caregivers. These significant results, which were larger in magnitude than expected, form the basis to further investigate the neuropsychiatric mechanisms that underlie improved mood through the use of this software technology,” stated Dr. Filoteo. “Digital therapeutics – the use of software to create a medical effect in patients – is an exciting new frontier for medicine,” said Edward Cox, CEO of Dthera. “This study supports that ReminX be used to scale out otherwise labor-intensive medical practices. We are excited at the opportunity to get our product in the hands of as many patients as possible.”
In the study, subjects were shown personalized video slideshow stories, which were created by the platform itself, displaying moments from various points in their life along with narration provided by family members.
The underlying science behind the product is called “Reminiscence Therapy.” Reminiscence Therapy (RT) is a well-known and well understood cognitive behavioral therapy, primarily used in the elderly, to both reduce anxiety and increase the quality of life in patients with dementia or those experiencing isolation. The therapy is usually provided either in a one-on-one setting or in groups. One of the key limitations to RT in the past is that it is very labor intensive, typically involving a family member or caregiver sitting with the patient manually going through the stories, and therefore is not easily scalable.
The product enables an immediate implementation of the core features of Reminiscence Therapy that can be provided to patients at any time. Dthera allows for the key elements of the therapy to be delivered through a Digital Therapeutic software. Driven by a proprietary artificial intelligence engine, Dthera’s software helps families populate stories so that patients in long term care facilities have constant access to personalized Reminiscence Therapy.
This study examined the impact of a digital therapeutic software system on emotional functioning in a group of patients with Dementia. The digital therapeutic software is based on Reminiscence Therapy and allows the uploading of pictures and narration to create slideshow stories depicting important moments in the patient’s life. Patients were evaluated in their home and the initial evaluation consisted of patients responding to questionnaires assessing their level of depression, anxiety, overall level of emotional distress, and health related quality of life. Patients’ caregivers were also asked to rate the patient’s level of emotional functioning. After the initial assessment, patients and their caregivers were instructed on how to use the digital therapeutic software and created a slideshow. Patients then viewed the slideshow and immediately after were re-assessed using the same set of questionnaires as prior to the viewing. Results indicated that patients reported significantly less anxiety, depression, and overall emotional distress after having viewed their story. Furthermore, patient’s caregivers also reported that the patient appeared less emotionally distressed. The effect sizes for the significant results were typically large and ranged from 0.76 to 0.91 (effect sizes are used to quantify the magnitude of a statistical effect, with 0.50 typically being viewed as a moderate effect and 0.80 being considered a large effect of an intervention). These effect sizes, which were larger than anticipated, suggest that digital therapeutic software can have an immediate and positive impact on emotional functioning in patients with Dementia. In addition, the accessibility and ease of use of the software system suggests that this technology holds great promise for bringing important aspects of Reminiscence Therapy to patients with Dementia who are suffering from various mood symptoms.
About Dthera Sciences:
Dthera Sciences (OTC:DTHR) is a publicly-traded Digital Therapeutics company based in San Diego that is working to improve Quality of Life (QoL) and reduce anxiety in patients with Alzheimer’s and Dementia. The company has developed a non-pharmaceutical quality of life therapy for Alzheimer’s and Dementia patients, specifically, the Company’s lead product, ReminX, is an artificial-intelligence-powered Digital Therapeutic designed to working improve quality of life and reduce anxiety in patients with Alzheimer’s and Dementia. For more information please visit www.dthera.com
About Digital Therapeutics:
Digital Therapeutics is a new subsection of digital health that strives to directly deliver a therapy via use or interaction with software technology. The goal of Digital Therapeutics is to mirror an effective treatment and use technology to scale it to a larger patient population, thereby amplifying doctors’ and nurses’ care, changing patient behavior, and most importantly, reducing cost of care.
About Reminiscence Therapy:
Reminiscence Therapy involves discussing and reviewing recognizable memories, typically by looking at photos, and hearing or discussing the familiar stories related to them. It has been shown to be very effective at reducing anxiety and increasing the overall Quality of Life (QoL) in Alzheimer’s and Dementia patients in numerous clinical trials and has been in use for nearly 30 years.
Dthera Sciences Forward-Looking Statement
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of medical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC’s website at www.sec.gov or without charge from the Company.
For more information: Brit Shapiro, 561-479-8566, firstname.lastname@example.org
SOURCE Dthera Sciences
Twist Bioscience CEO Named Distinguished Alumnus of the University of Houston College of Natural Sciences and Mathematics
SAN FRANCISCO, April 10, 2017 /PRNewswire/ — Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that Emily Leproust, Ph.D., CEO of Twist Bioscience, was named as a 2016 Distinguished Alumnus of the University of Houston College of Natural Sciences and Mathematics (NSM). Leproust was honored at the NSM 40th Anniversary Impact Gala on April 8, 2017.
The NSM Distinguished Alumni Awards, established in honor of the College’s 40th anniversary, are bestowed upon alumni of the College of Natural Sciences and Mathematics for exceptional achievement in their professional field, involvement in the community and demonstrated innovative change to improve the lives of others through their work.
“I am honored to be included among the inaugural group of alumni selected for this award,” said Dr. Leproust. “My experience and education from the University of Houston’s College of Natural Sciences and Mathematics provided a strong foundation for launching my career and success in an entrepreneurial venture, and I look forward to remaining a part of this thriving community.”
About Twist Bioscience
At Twist Bioscience, our expertise is accelerating science and innovation by leveraging the power of scale. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high throughput silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production, which in turn, expedites the design, build and test cycle to enable personalized medicines, pharmaceuticals, sustainable chemical production, improved agriculture production, diagnostics and biodetection. We are also developing new technologies to address large scale data storage. For more information, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at https://twitter.com/TwistBioscience.
SOURCE Twist Bioscience
Special Meeting of Mast Therapeutics Stockholders to Be Held on April 21, 2017
SAN DIEGO and AUSTIN, Texas, April 10, 2017 /PRNewswire/ — Mast Therapeutics, Inc. (NYSE MKT: MSTX) and Savara Inc., a privately-held, clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, announced today that, pending completion of their proposed merger, the combined company’s common stock has been approved for listing on the Nasdaq Capital Market under the symbol “SVRA.” Trading on the Nasdaq Capital Market is expected to commence on the first business day after completion of the merger. Mast’s common stock is expected to continue to trade on the NYSE MKT until completion of the merger. Mast has provided notification to the NYSE MKT of its intent to voluntarily withdraw its common stock from listing and trading on NYSE MKT in connection with the completion of the merger and the move to Nasdaq.
“As home to many innovative and growth-oriented life science companies, Nasdaq is a natural fit for Savara,” said Rob Neville, Chief Executive Officer of Savara. “We believe the move to Nasdaq will provide strong visibility for our stock, good trading liquidity in our shares, and provide the company with greater exposure to institutional investors.”
Mast will hold a special meeting of its stockholders to vote on matters related to the proposed merger with Savara on April 21, 2017 at 9:00 a.m. Pacific Time. Mast’s stockholders of record as of the close of business on March 13, 2017 are entitled to receive notice of, and to vote at, the special meeting. The merger is expected to close promptly after the Mast special meeting, subject to the approval of the Mast stockholders and the satisfaction or waiver of the other closing conditions in the merger agreement between the companies.
The merger has been unanimously approved by the boards of directors of both companies and Mast urges its stockholders to vote “FOR” the merger and the other proposals set forth in the proxy statement/prospectus/ information statement dated March 15, 2017, a copy of which has been provided to Mast stockholders of record as of March 13, 2017. Not voting is the same as voting against the transaction. Given that Mast stockholder approval must exceed 50% of Mast’s outstanding common stock as of the record date, every vote in favor of each proposal is extremely important no matter how many or how few shares you own. Please vote TODAY!
THE MERGER WILL NOT GO FORWARD UNLESS
THE MERGER, REVERSE STOCK SPLIT AND NAME CHANGE PROPOSALS
ARE ALL APPROVED.
If you are a Mast stockholder and you have questions or require assistance in submitting your proxy or voting your shares, please contact Mast’s proxy solicitor:
ADVANTAGE PROXY, INC.
Toll Free: 1-877-870-8565
About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. Mast’s lead product candidate, AIR001, is a sodium nitrite solution for intermittent inhalation via nebulization in Phase 2 clinical development for the treatment of heart failure with preserved ejection fraction (HFpEF). More information can be found on Mast’s web site at www.masttherapeutics.com. Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.
Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara’s pipeline comprises AeroVanc, a Phase 3 ready inhaled vancomycin, and Molgradex, a Phase 2/3 stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF. Savara’s strategy involves expanding its pipeline of best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, creating and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com.
Additional Information about the Proposed Merger and Where to Find It
In connection with the proposed merger, Mast Therapeutics has filed relevant materials with the Securities and Exchange Commission, or the SEC, including a registration statement on Form S-4 that contains a proxy statement, prospectus and information statement. The registration statement was declared effective by the SEC on March 15, 2017. The proxy statement/prospectus/information statement and other relevant materials, and any other documents filed by Mast with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Mast by directing a written request to: Mast Therapeutics, Inc. 3611 Valley Centre Drive, Suite 500, San Diego, California 92130, Attn: Investor Relations. Investors and security holders of Mast and Savara are urged to read the proxy statement/prospectus/information statement and other relevant materials before making any voting or investment decision with respect to the proposed merger.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Participants in the Solicitation
Mast and its directors and executive officers and Savara and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Mast and Savara in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the proposed merger is included in the proxy statement/prospectus/information statement referred to above. Additional information regarding the directors and executive officers of Mast is also included in Mast’s Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the SEC on March 6, 2017. These documents are available free of charge at the SEC web site (www.sec.gov) and from Investor Relations at Mast at the address described above.
Forward Looking Statements
Mast and Savara caution you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Such statements include, but are not limited to, statements regarding the structure, timing and completion of the proposed merger; expectations regarding listing and trading of Mast’s common stock on the NYSE MKT and of the combined organization’s common stock on the Nasdaq Capital Market; the capitalization, resources, ownership structure of the combined organization; the nature, strategy and focus of the combined organization; the safety, efficacy and projected development timeline and commercial potential of any product candidates; the executive officer and board structure of the combined organization; and the expectations regarding voting by Mast stockholders. Mast and/or Savara may not actually achieve the proposed merger, or any plans or product development goals in a timely manner, if at all, or otherwise carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Mast’s and Savara’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with stockholder approval of and the ability to consummate the proposed merger through the process being conducted by Mast and Savara, the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for combined company operations and to conduct or continue planned clinical development programs, the timing and ability of Mast or Savara to raise additional equity capital to fund continued operations; the ability to successfully develop any of Mast’s and/or Savara’s product candidates, and the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates that are safe and effective for use as human therapeutics. Risks and uncertainties facing Mast, Savara and the combined organization and risks related to the proposed merger are described more fully in the proxy statement/prospectus/information statement referred to above. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Neither Mast nor Savara undertakes any obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
SOURCE Mast Therapeutics, Inc.
When seeking a new opportunity, the most important items to consider are the reputation of the company and how successful you will be working there. If youFrom Invetech – Mon, 10 Apr 2017 02:16:34 GMT – View all San Diego jobs
2-3 years’ minimum relevant experience preferably in Biotech industry as a sales representative. Develop new Biotech customers within the region by actively…
From Invetech – Mon, 10 Apr 2017 02:15:10 GMT – View all San Diego jobs
San Diego Biomedical Research Institute (SDBRI) is seeking candidates for the full-time Research Technician position in the laboratory of Dr. Wael ElShamy. His laboratory investigates BRCA1-IRIS and geminin oncogenic functions in promoting breast and […
Business Development Manager – Biotechnology – San DiegoTerritory. Pall Corporation is a global leader in high-tech filtration, separation, and purification,…From Kollmorgen – Mon, 10 Apr 2017 01:02:02 GMT – View all San Diego jobs